Comparison of Prolonged Exposure vs Cognitive Processing Therapy for Treatment of Posttraumatic Stress Disorder Among US Veterans: A Randomized Clinical Trial.

Importance: Posttraumatic stress disorder (PTSD) is a prevalent and serious mental health problem. Although there are effective psychotherapies for PTSD, there is little information about their comparative effectiveness. Objective: To compare the effectiveness of prolonged exposure (PE) vs cognitive processing therapy (CPT) for treating PTSD in veterans. Design, Setting, and Participants: This randomized clinical trial assessed the comparative effectiveness of PE vs CPT among veterans with military-related PTSD recruited from outpatient mental health clinics at 17 Department of Veterans Affairs medical centers across the US from October 31, 2014, to February 1, 2018, with follow-up through February 1, 2019. The primary outcome was assessed using centralized masking. Tested hypotheses were prespecified before trial initiation. Data were analyzed from October 5, 2020, to May 5, 2021. Interventions: Participants were randomized to 1 of 2 individual cognitive-behavioral therapies, PE or CPT, delivered according to a flexible protocol of 10 to 14 sessions. Main Outcomes and Measures: The primary outcome was change in PTSD symptom severity on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) from before treatment to the mean after treatment across posttreatment and 3- and 6-month follow-ups. Secondary outcomes included other symptoms, functioning, and quality of life. Results: Analyses were based on all 916 randomized participants (730 [79.7%] men and 186 [20.3%] women; mean [range] age 45.2 [21-80] years), with 455 participants randomized to PE (mean CAPS-5 score at baseline, 39.9 [95% CI, 39.1-40.7] points) and 461 participants randomized to CPT (mean CAPS-5 score at baseline, 40.3 [95% CI, 39.5-41.1] points). PTSD severity on the CAPS-5 improved substantially in both PE (standardized mean difference [SMD], 0.99 [95% CI, 0.89-1.08]) and CPT (SMD, 0.71 [95% CI, 0.61-0.80]) groups from before to after treatment. Mean improvement was greater in PE than CPT (least square mean, 2.42 [95% CI, 0.53-4.31]; P = .01), but the difference was not clinically significant (SMD, 0.17). Results for self-reported PTSD symptoms were comparable with CAPS-5 findings. The PE group had higher odds of response (odds ratio [OR], 1.32 [95% CI, 1.00-1.65]; P < .001), loss of diagnosis (OR, 1.43 [95% CI, 1.12-1.74]; P < .001), and remission (OR, 1.62 [95% CI, 1.24-2.00]; P < .001) compared with the CPT group. Groups did not differ on other outcomes. Treatment dropout was higher in PE (254 participants [55.8%]) than in CPT (215 participants [46.6%]; P < .01). Three participants in the PE group and 1 participant in the CPT group were withdrawn from treatment, and 3 participants in each treatment dropped out owing to serious adverse events. Conclusions and Relevance: This randomized clinical trial found that although PE was statistically more effective than CPT, the difference was not clinically significant, and improvements in PTSD were meaningful in both treatment groups. These findings highlight the importance of shared decision-making to help patients understand the evidence and select their preferred treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT01928732.

Daily versus monthly reporting of post-traumatic symptoms: A study of reliability across time and instruments.

This study compared daily-versus-monthly self-ratings of post-traumatic symptoms using two similar but not wholly identical measures. The rationale was to determine whether (1) posttraumatic dissociation and/or minimization or (2) certain biases (more recent symptoms, more severe symptoms, practice effect, Hawthorne effect) might undermine symptom recall. Seventeen voluntary participants provided daily self-ratings for an average of 11.6 months. Nine male veterans had combat trauma; one also experienced sexual trauma. Four women had experienced sexual assault, and four women had other trauma. The monthly measure consisted of the self-rated Posttraumatic Stress Disorder (PTSD) Checklist (PCL), and daily ratings employed the self-rated PTSD Life Chart that we devised. These data revealed that people with Posttraumatic Stress Disorder (PTSD) produced monthly ratings that reflected their day-to-day symptom experience over the previous month, despite the dissociation and minimization that often accompanies PTSD. Initial practice effect occurred in the first month, but other biases (recent symptoms, severe symptoms, Hawthorne effect) were not demonstrated.

Daily charting of posttraumatic stress symptoms: a pilot study.

This pilot study describes a prospective life-charting method for posttraumatic stress (PTS) symptoms. This method summarizes daily symptoms, functional impairment, life events, substance use, and treatment. Findings include experience with 17 cases over periods lasting from 3 to 25 months, with a description of 4 case examples that are characteristic of the pilot sample. People with posttraumatic stress disorder (PTSD) can complete day charting of their symptoms over an extended period of time. Some people reported that day charting distressed them mildly as they analyzed daily thoughts or feelings that they ordinarily avoided or pushed from awareness. Nonetheless, most people reported that they learned and benefited from daily symptom charting. In addition to enhancing patient self-understanding (or "insight"), the method may prove useful in assessing treatments for PTSD. Finally, these preliminary findings have suggested hypotheses regarding the clinical phenomenology and course of PTSD. For example, PTS symptom cluster exacerbation, severity, and duration appear to be highly consistent within any given patient, but highly variable across patients. Daily charting of PTS symptoms over prolonged periods is feasible. This prospective PTSD symptom charting method may have therapeutic, clinical, and research potential for understanding individual and group patterns in PTSD over time.